Shortwave Life Sciences PLC - London-based drug development for mental health - Changes name from Psych Capital following the acquisition of Shortwave Pharma Inc last year. Says the new name reflects its focus on mental health, particularly eating disorders. This includes psychedelics-based therapies.

"Eating disorders, including anorexia nervosa, bulimia nervosa, and binge-eating disorder, represent a significant global health challenge, affecting millions of individuals worldwide and growing at an alarming rate," the company says. "Shortwave Life Sciences is committed to leveraging cutting-edge drug design, novel delivery methods, and decades of drug development expertise to develop and support transformative therapies for these debilitating conditions."

Current stock price: 2.40 pence

12-month change: down from 4.125p

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.